📊 INBS Key Takeaways
Is Intelligent Bio Solutions Inc.. (INBS) a Good Investment?
INBS is a pre-commercial medical device company with critically unsustainable fundamentals: $5.6M operating losses on just $2M revenue, negative -$4.4M operating cash burn, and only $740K cash reserves representing approximately 2 months of runway. Revenue is declining while operating losses persist, and despite a reasonable 48.7% gross margin, the company operates at a -280% operating margin indicating severe operational inefficiency and likely excessive R&D spending relative to commercial progress.
Fundamentals show contracting revenue, deeply negative margins, and persistent cash burn that far exceeds the company’s modest cash balance, implying a short runway and likely need for external financing. While gross margins are acceptable and leverage is low, the current scale is insufficient to cover operating costs, and profitability improvements are minimal.
Why Buy Intelligent Bio Solutions Inc.. Stock? INBS Key Strengths
- Gross margin of 48.7% suggests underlying product value and pricing power
- Low leverage with Debt/Equity of 0.15x limits downside risk to creditors
- Current ratio of 2.37x and Quick ratio of 2.26x provide near-term liquidity cushion
- Decent gross margin (~49%) suggests viable unit economics at scale
- Low leverage (Debt/Equity ~0.15x) reduces insolvency risk from debt
- Solid current and quick ratios indicate near-term solvency
INBS Stock Risks: Intelligent Bio Solutions Inc.. Investment Risks
- Severe liquidity crisis: $740K cash against $4.4M quarterly operating burn equals 2-month runway before potential insolvency
- Revenue declining -1.9% YoY in early-stage company indicates fundamental demand issues or market acceptance problems
- Operating margin of -280.6% reflects unsustainable cost structure with R&D and SG&A far exceeding revenue capacity
- Negative free cash flow of -$4.6M per period indicates company cannot fund operations without external capital
- Sustained operating losses and FCF burn with limited cash (~$0.74M)
- Revenue decline (-1.9% YoY) raises execution and demand concerns
- High dilution/going-concern risk if additional capital is required
Key Metrics to Watch
- Cash balance trajectory and monthly burn rate (critical path to solvency)
- Revenue growth inflection point (currently declining, needs immediate reversal)
- Operating expense reduction or major commercial milestone/partnership (path to profitability)
- Quarterly revenue growth (YoY/QoQ)
- Operating cash flow (burn) vs cash balance/runway
Intelligent Bio Solutions Inc.. (INBS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.37x current ratio provides a solid financial cushion.
INBS Profit Margin, ROE & Profitability Analysis
INBS vs Healthcare Sector: How Intelligent Bio Solutions Inc.. Compares
How Intelligent Bio Solutions Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Intelligent Bio Solutions Inc.. Stock Overvalued? INBS Valuation Analysis 2026
Based on fundamental analysis, Intelligent Bio Solutions Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Intelligent Bio Solutions Inc.. Balance Sheet: INBS Debt, Cash & Liquidity
INBS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Intelligent Bio Solutions Inc..'s revenue has grown significantly by 57% over the 5-year period, indicating strong business expansion. The most recent EPS of $-6.38 indicates the company is currently unprofitable.
INBS Revenue Growth, EPS Growth & YoY Performance
INBS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $607.5K | -$2.2M | $-2.82 |
| Q1 2026 | $872.3K | -$2.7M | $-0.35 |
| Q3 2025 | $728.9K | -$2.5M | $-0.44 |
| Q2 2025 | $607.5K | -$2.0M | $-0.50 |
| Q1 2025 | $796.1K | -$2.4M | $-0.70 |
| Q3 2024 | $457.1K | -$3.0M | $-1.43 |
| Q2 2024 | $356.7K | -$420.6K | $-2.07 |
| Q1 2024 | $796.1K | -$1.2M | $-1.04 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Intelligent Bio Solutions Inc.. Dividends, Buybacks & Capital Allocation
INBS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Intelligent Bio Solutions Inc.. (CIK: 0001725430)
📋 Recent SEC Filings
❓ Frequently Asked Questions about INBS
What is the AI rating for INBS?
Intelligent Bio Solutions Inc.. (INBS) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are INBS's key strengths?
Claude: Gross margin of 48.7% suggests underlying product value and pricing power. Low leverage with Debt/Equity of 0.15x limits downside risk to creditors. ChatGPT: Decent gross margin (~49%) suggests viable unit economics at scale. Low leverage (Debt/Equity ~0.15x) reduces insolvency risk from debt.
What are the risks of investing in INBS?
Claude: Severe liquidity crisis: $740K cash against $4.4M quarterly operating burn equals 2-month runway before potential insolvency. Revenue declining -1.9% YoY in early-stage company indicates fundamental demand issues or market acceptance problems. ChatGPT: Sustained operating losses and FCF burn with limited cash (~$0.74M). Revenue decline (-1.9% YoY) raises execution and demand concerns.
What is INBS's revenue and growth?
Intelligent Bio Solutions Inc.. reported revenue of $2.0M.
Does INBS pay dividends?
Intelligent Bio Solutions Inc.. does not currently pay dividends.
Where can I find INBS SEC filings?
Official SEC filings for Intelligent Bio Solutions Inc.. (CIK: 0001725430) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is INBS's EPS?
Intelligent Bio Solutions Inc.. has a diluted EPS of $-6.27.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is INBS a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Intelligent Bio Solutions Inc.. has a STRONG SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is INBS stock overvalued or undervalued?
Valuation metrics for INBS: ROE of -51.0% (sector avg: 15%), net margin of -281.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy INBS stock in 2026?
Our dual AI analysis gives Intelligent Bio Solutions Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is INBS's free cash flow?
Intelligent Bio Solutions Inc..'s operating cash flow is $-4.4M, with capital expenditures of $138.6K. FCF margin is -226.7%.
How does INBS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -281.8% (avg: 12%), ROE -51.0% (avg: 15%), current ratio 2.37 (avg: 2).